Real-world experience with ruxolitinib for steroid-refractory acute graft-versus-host disease: a single center experience.
Acute graft-versus-host disease
Allogeneic hematopoietic stem cell transplantation
Corticosteroids
Refractoriness
Ruxolitinib
Journal
International journal of hematology
ISSN: 1865-3774
Titre abrégé: Int J Hematol
Pays: Japan
ID NLM: 9111627
Informations de publication
Date de publication:
Dec 2022
Dec 2022
Historique:
received:
15
06
2022
accepted:
29
07
2022
revised:
28
07
2022
pubmed:
17
8
2022
medline:
22
11
2022
entrez:
16
8
2022
Statut:
ppublish
Résumé
Steroid-refractory acute graft-versus-host disease (SR-aGVHD) remains a major cause of morbidity and mortality after allogeneic hematopoietic stem cell transplantation (allo-HSCT). Ruxolitinib (RUX), an oral JAK1 and JAK2 inhibitor, has recently been approved for patients with SR-aGVHD. The aim of this study was to evaluate RUX efficacy and toxicity in a real-world setting. Eighteen patients received RUX at 5 mg or 10 mg twice a day after a median 3 lines of prior unsuccessful immunosuppressive therapy. Median time on RUX therapy was 28 days (range 7-129). Five patients (28%) responded to RUX, including 4 complete responses and 1 partial response. Response to RUX was irrespective of aGVHD grade and the number of involved organs. One-year overall survival (OS) was 60% for RUX-responders versus 31% for non-responders (p = ns). Treatment duration greater than 29.5 days was found to have a positive impact on OS (p < 0.007). Major adverse events during RUX treatment were grade 3-4 thrombocytopenia (61% of patients) and cytomegalovirus reactivation (50%). After median follow-up of 55 days (range 29-706), 14 patients (78%) died, mainly due to further progression of GVHD. RUX may represent a valuable therapeutic option for some patients with advanced SR-aGVHD, but more studies are warranted.
Identifiants
pubmed: 35972605
doi: 10.1007/s12185-022-03434-5
pii: 10.1007/s12185-022-03434-5
pmc: PMC9668796
doi:
Substances chimiques
ruxolitinib
82S8X8XX8H
Pyrimidines
0
Pyrazoles
0
Nitriles
0
Steroids
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
922-928Informations de copyright
© 2022. The Author(s).
Références
Bone Marrow Transplant. 2020 Mar;55(3):641-648
pubmed: 31700138
Biol Blood Marrow Transplant. 2019 Aug;25(8):1689-1694
pubmed: 30965140
Oncologist. 2020 Feb;25(2):e328-e334
pubmed: 32043777
Blood. 2020 May 14;135(20):1739-1749
pubmed: 32160294
Blood. 2013 Aug 15;122(7):1192-202
pubmed: 23770777
Front Immunol. 2021 Nov 17;12:760199
pubmed: 34868001
Drug Des Devel Ther. 2021 Nov 30;15:4875-4883
pubmed: 34880598
Blood. 2014 Jun 12;123(24):3832-42
pubmed: 24711661
Blood. 2018 Apr 19;131(16):1858-1869
pubmed: 29463561
PLoS One. 2014 Oct 07;9(10):e109799
pubmed: 25289677
Leukemia. 2015 Oct;29(10):2062-8
pubmed: 26228813
Bone Marrow Transplant. 2014 Feb;49(2):168-73
pubmed: 23892326
Biol Blood Marrow Transplant. 2016 Jan;22(1):4-10
pubmed: 26386318
Sci Rep. 2021 Apr 19;11(1):8501
pubmed: 33875780
N Engl J Med. 2020 May 7;382(19):1800-1810
pubmed: 32320566
Biomed Res Int. 2019 Mar 06;2019:8163780
pubmed: 30956985
J Exp Pharmacol. 2020 Nov 26;12:549-557
pubmed: 33273867
Biol Blood Marrow Transplant. 2012 Aug;18(8):1150-63
pubmed: 22510384
J Natl Cancer Inst. 1959 Jul;23(1):75-89
pubmed: 13673271
Leukemia. 2020 May;34(5):1229-1240
pubmed: 32242050
Bone Marrow Transplant. 1995 Jun;15(6):825-8
pubmed: 7581076
BioDrugs. 2021 Jan;35(1):19-33
pubmed: 33201499
J Biol Chem. 2007 Jul 13;282(28):20059-63
pubmed: 17502367
Transplant Cell Ther. 2021 Apr;27(4):332.e1-332.e8
pubmed: 33836880
Blood. 2020 Oct 22;136(17):1903-1906
pubmed: 32756949